Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DIGOXIN

All products: general benefit

Auro-Digoxin · DIN 02554399 · 0.0625mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Digoxin · DIN 02554399 Manufacturer: Auro Pharma Inc.; listing date 2025-11-28 Health Canada: Marketed since 2025-07-22 · brand AURO-DIGOXIN · ATC C01AA05 DIGOXIN · form Tablet · route Oral · ingredients DIGOXIN 0.0625 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Digoxin: Formulary list price $0.1089/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.1089 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104325 · Verify on the e-Formulary ↗ (DIN 02554399)

Source record
DIN 02554399: Auro-Digoxin Raw flags: chronicUseMed=Y, sec3=Y Item: 240400090; group id 279; item number 0581; lccId None; manufacturer id AUR Source form: Tab; strength: 0.0625mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.1089; ministry $0.1089 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554399 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104325
Interchangeable products
Jamp Digoxin · DIN 02498502 · $0.1089 PMS-Digoxin · DIN 02335700 · $0.1089
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02554399
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (24:04 Cardiac Drugs) and how they are covered

Matched class: 24:04 Cardiac Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ATENOLOL, PROPAFENONE HCL Some products covered without a code (check the product listing): ACEBUTOLOL HCL, AMIODARONE HCL, AMLODIPINE, BISOPROLOL FUMARATE, DILTIAZEM HCL, DISOPYRAMIDE, FLECAINIDE ACETATE, METOPROLOL TARTRATE, MEXILETINE HCL, NADOLOL, NIFEDIPINE, PROPRANOLOL, SOTALOL HCL, TIMOLOL MALEATE, VERAPAMIL HCL 24:00 CARDIOVASCULAR DRUGS

RANOLAZINE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · ER Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:00 24:04 Cardiac Drugs

ACEBUTOLOL HCL

· 9 products · Listed, not a benefit (3), General benefit (6) · strengths: 100mg, 200mg, 400mg · Tab

AMIODARONE HCL

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 200mg · Tab

AMLODIPINE

· 56 products · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44) · strengths: 1mg/mL, 2.5mg, 5mg, 10mg · Oral Sol, Tab

ATENOLOL

· 26 products · General benefit · strengths: 50mg, 100mg · Tab

BISOPROLOL FUMARATE

· 20 products · General benefit (18), Listed, not a benefit (2) · strengths: 1.25mg, 2.5mg, 5mg, 10mg · Tab

DILTIAZEM HCL

· 93 products · General benefit (91), Listed, not a benefit (2) · strengths: 120mg, 180mg, 240mg, 300mg, 360mg, 30mg, 60mg · ER Tab, LA Cap, SR Cap, Tab

DISOPYRAMIDE

· 3 products · Listed, not a benefit (1), General benefit (1), Temporary benefit (1) · strengths: 100mg · Cap

FLECAINIDE ACETATE

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 50mg, 100mg · Tab

METOPROLOL TARTRATE

· 28 products · Listed, not a benefit (6), General benefit (22) · strengths: 100mg, 200mg, 50mg · LA Tab, Tab

MEXILETINE HCL

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 100mg, 200mg · Cap

NADOLOL

· 8 products · Listed, not a benefit (3), General benefit (5) · strengths: 40mg, 80mg, 160mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:04 and 9 more
Full class listing Related classes: 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: atrial fibrillation
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. DABIGATRAN ETEXILATE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (4) INDICATIONS AND CLINICAL USE PRADAXA (dabigatran etexilate) is indicated for the: • prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery • treatment of venous thromboembolism events (deep vein thrombosis [DVT], pulmonary embolism [PE]) and prevention of recurrent DVT and PE • prevention of stroke and systemic embolism in patients with atrial fibrillation, in whom anticoagulation is appropriate Geriatrics (>65 years of age): Most older subjects demonstrate an increase in exposure to dabigatran, usually in association with age-related decline of renal function (see WARNINGS AND PRECAUTIONS, Renal, and DOSAGE AND ADMINISTRATION, Renal Impairment). PM: https://pdf.hres.ca/dpd_pm/00080323.PDF; date APR 22, 2025; DIN 02312441; fetched 2026-09-10 Product monograph EDOXABAN · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) 1 INDICATIONS Sandoz Edoxaban (edoxaban tablets) is indicated for: • Prevention of stroke and systemic embolic events in patients with atrial fibrillation, in whom anticoagulation is appropriate. PM: https://pdf.hres.ca/dpd_pm/00080468.PDF; date MAY 05, 2025; DIN 02553414; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS pms-DIGOXIN (digoxin tablets and digoxin oral solution) are indicated for: • Congestive Heart Failure: pms-DIGOXIN is indicated for the treatment of mild to moderate heart failure. pms-DIGOXIN increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, pms-DIGOXIN should be used with a diuretic and angiotensin-converting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. Digoxin is usually continued after failure is controlled unless some known precipitating factor is corrected. Studies have shown that withdrawal of digoxin may worsen functional status, exercise capacity, and the left ventricular ejection fraction in patients with heart failure. In patients in whom digoxin may be difficult to regulate, or in whom the risk of toxicity may be great (e.g., patients with unstable renal function or whose potassium levels tend to fluctuate) a cautious withdrawal of digoxin may be considered. I… https://pdf.hres.ca/dpd_pm/00069390.PDF PM date: NOV 23, 2022 Source product: PMS-DIGOXIN; DIN 02242320; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.